VLVbio AB is a Swedish biotechnology company that combines the innovative mindset and energy of a young  company, founded in 2013, with the history and built-in expertise of a Product Line invented more than a decade ago at the Karolinska Institute in Stockholm, Sweden.

The PEVIVA Product Line was invented at the Karolinska Institute in Stockholm, and is based on unique antibodies measuring apoptosis and total cell death. Since the invention, the products have been used globally  in academia, industry and in healthcare. Measuring apoptosis and levels of total cell death can be of interest in the diagnosis and treatment follow-up of patients suffering from liver diseases such as NASH and ASH, in the development of new drugs and when assessing toxicological effects of pharmaceuticals and other substances.